Salidroside, the main active compound of the arctic root Rhodiola rosea, most consistently supports modest reductions in fatigue, stress, and burnout, mostly shown for the standardized whole-root extract. Effects on mood, thinking, and physical performance are smaller and less certain. Broad protective and longevity actions remain unproven in people. Generally well tolerated; a low-risk stress-and-fatigue aid. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 75–90 mg/dL | Detects additive blood-sugar lowering |
| HbA1c | < 5.4% | Tracks longer-term blood-sugar effect |
| hs-CRP | < 1.0 mg/L | Gauges the anti-inflammatory effect |
| Morning cortisol | Mid-reference range | Reflects stress-axis modulation |
| Blood pressure and resting heart rate | < 120/80 mmHg; 50–70 bpm | Screens for blood-pressure/heart-rate effects |
| TSH | 0.5–2.5 mIU/L | Rules out thyroid causes of fatigue |
| Hemoglobin (Hb) | 13–15 g/dL (adult range) | Screens for effects on red-cell production |
| ALT / AST | ALT < 25 U/L; AST < 25 U/L | Confirms liver tolerability |
Cadence: Baseline, then recheck at 4–8 weeks; every 6–12 months during continued use, with more frequent glucose checks if on glucose-lowering therapy